Published in Lab Business Week, January 16th, 2005
In respect of this financing, Biomira intends to file shortly in Canada a prospectus supplement to its July 13, 2004 Base Shelf Prospectus and in the United States a prospectus supplement to its July 13, 2004 F-10 Registration Statement. The financing is expected to close at the earliest opportunity and is subject to regulatory approval.
The company will be offering up to 3,891,051 common shares at an issue price of US$2.57, which represents a discount of 15% to the US$3.02 closing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.